Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features

Protein gene product 9.5 (PGP9.5) is a neurospecific peptide that removes ubiquitin from ubiquitinated proteins and prevents them being targeted for degradation by proteosomes. Its expression is a potential marker of non‐small lung cancer, invasive colorectal cancer and esophageal squamous cell carcinoma. Gallbladder (GB) cancer is the most common malignant tumor of the biliary tract and is usually associated with gallstone disease, a late diagnosis, unsatisfactory treatment and a poor prognosis. To understand the role of PGP9.5 in GB cancer, we examined the methylation status of its promoter and its expression in surgical biopsy samples. Formalin‐fixed, paraffin‐embedded tumors and non‐neoplastic GB tissues (22 carcinomas, eight adenomas, 26 normal epithelia) were collected from patients who had undergone surgical resection. The methylation status of the promoter region of the PGP9.5 gene was determined by methylation‐specific polymerase chain reaction, and the expression of PGP9.5 was examined by immunohistochemistry using tissue microarrays. PGP9.5 promoter was methylated in 84.6% (22/26) of normal GB epithelium, 37.5% (3/8) of adenomas and 27.2% (6/22) of carcinomas. Most tumors with an unmethylated promoter exhibited positive staining for PGP9.5 in epithelial and neoplastic cells, but no PGP9.5 expression was observed in normal epithelia or in tumor tissues with a methylated promoter. No correlation was found between promoter hypomethylation of PGP9.5 and clinicopathological findings (i.e. age, sex, histological type or grade, N‐status, invasion depth or tumor stage) whereas PGP9.5 hypomethylation was found to be inversely correlated with the presence of a gallstone (P = 0.015). These results suggest that PGP9.5 promoter hypomethylation could be a reliable marker for GB cancer and that DNA hypomethylation might play an important role in re‐expression of the PGP9.5 gene in GB cancer. (Cancer Sci 2006; 97: 1205–1210)

[1]  I. Wistuba,et al.  Aberrant methylation of Reprimo in human malignancies , 2005, International journal of cancer.

[2]  Yoichi Tanaka,et al.  PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. , 2005, Cancer research.

[3]  Y. Kodera,et al.  Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinoma. , 2004, Anticancer research.

[4]  T. Sugihara,et al.  Expression of protein gene product 9·5 (PGP9·5)/ubiquitin‐C‐terminal hydrolase 1 (UCHL‐1) in human myeloma cells , 2004, British journal of haematology.

[5]  I. Wistuba,et al.  Aberrant Promoter Hypermethylation of Multiple Genes in Gallbladder Carcinoma and Chronic Cholecystitis , 2004, Clinical Cancer Research.

[6]  T. Sugai,et al.  Promoter hypermethylation of DAP‐kinase is associated with poor survival in primary biliary tract carcinoma patients , 2004, Cancer science.

[7]  I. Wistuba,et al.  Gallbladder cancer: lessons from a rare tumour , 2004, Nature Reviews Cancer.

[8]  S. Nomoto,et al.  Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing , 2004, Cancer Research.

[9]  M. Urashima,et al.  Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. , 2004, Cancer letters.

[10]  T Takano,et al.  PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. , 2004, European journal of cancer.

[11]  M. Pandey,et al.  Carcinoma of the Gallbladder , 2001, Digestive Diseases and Sciences.

[12]  Hiroshi Nakayama,et al.  PGP9.5 overexpression in esophageal squamous cell carcinoma. , 2003, Hepato-gastroenterology.

[13]  J. Herman,et al.  Progression of Gene Hypermethylation in Gallstone Disease Leading to Gallbladder Cancer , 2003, Annals of Surgical Oncology.

[14]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[15]  J. Cameron,et al.  Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. , 2003, Cancer research.

[16]  A. Godwin,et al.  Hypomethylation of the Synuclein γ Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma , 2003 .

[17]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[18]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Neuroscience.

[19]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[20]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[21]  J. Minna,et al.  High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma , 2002, British Journal of Cancer.

[22]  A. Maitra,et al.  Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. , 2002, The American journal of pathology.

[23]  J. Jen,et al.  Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1 , 2002, Oncogene.

[24]  J. Cameron,et al.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. , 2002, The American journal of pathology.

[25]  A. Nakao,et al.  PGP9.5 as a marker for invasive colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  I. Wistuba,et al.  Epidemiology and Molecular Pathology of Gallbladder Cancer , 2001, CA: a cancer journal for clinicians.

[27]  W. Hong,et al.  Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. , 2001, Cancer research.

[28]  H. Sasaki,et al.  Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. , 2001, Japanese journal of clinical oncology.

[29]  J. Jen,et al.  Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. , 2001, Cancer letters.

[30]  Y. Liaw,et al.  Genome-wide hypomethylation in hepatocellular carcinogenesis. , 2001, Cancer research.

[31]  Fernando Silvio Cavalcante Pimentel,et al.  Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. , 2001, Cancer research.

[32]  A. Nakao,et al.  PGP9.5 as a prognostic factor in pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[34]  M. Pagano,et al.  Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.

[35]  日高 英二.  Losses of heterozygosity on chromosomes 17p and 9p/18q may play important roles in early and advanced phases of gallbladder carcinogenesis , 2000 .

[36]  S. Goodman,et al.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.

[37]  Y. Kato,et al.  Losses of heterozygosity on chromosomes 17p and 9p/18q my play important roles in early and advanced phases of gallbladder carcinogenesis , 1999, Journal of Cancer Research and Clinical Oncology.

[38]  J. Jen,et al.  Serial analysis of gene expression in non-small cell lung cancer. , 1998, Cancer research.

[39]  M. Schmitt,et al.  Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). , 1998, International journal of oncology.

[40]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[41]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[42]  M. Minegishi,et al.  Detection of the PGP9.5 and tyrosine hydroxylase mRNAs for minimal residual neuroblastoma cells in bone marrow and peripheral blood. , 1998, The Tohoku journal of experimental medicine.

[43]  A. Harris,et al.  The ubiquitin-proteasome pathway in cancer. , 1998, British Journal of Cancer.

[44]  C. Moskaluk,et al.  Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. , 1997, The American journal of pathology.

[45]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Maeda,et al.  K-ras gene mutation in gall bladder carcinomas and dysplasia. , 1996, Gut.

[47]  K. Hanada,et al.  K‐ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct , 1996, Cancer.

[48]  I. Wistuba,et al.  Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. , 1995, Cancer research.

[49]  K. Joh,et al.  Ubiquitin immunoreactivity in human malignant tumours. , 1991, British Journal of Cancer.

[50]  K D Wilkinson,et al.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.

[51]  M. Ebara,et al.  Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. , 1985, Gastroenterology.